These results suggest that restoration of miR-30a-5p expression could serve as a promising therapeutic approach to counteract the progression of ES by disrupting the EWS-FLI1/CD99 oncogenic axis [125]. The gene discussed is FLI1; the disease is Ewing sarcoma.